Skip to main navigation Skip to search Skip to main content

Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Research output: Contribution to journalArticlepeer-review

Abstract

Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

Original languageEnglish (US)
Pages (from-to)1309-1311
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number6
DOIs
StatePublished - Mar 15 2013

Funding

FundersFunder number
National Institute of Health-National Cancer InstituteR00CA151457

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies'. Together they form a unique fingerprint.

    Cite this